RYAH Medtech, Inc. (“RYAH” or the “Company”), announced today that it has entered into a strategic arrangement with DelleD SAS, a biotech company specialized in medical cannabis in France, with an aim to participate in the French National Medical Cannabis Experimentation and ultimately, distribute the RYAH Dry-Herb Inhaler and software platform throughout the country.

ryah dry herb inhaler


The agreement entails two sequential phases of collaboration:

Experimentation phase: DelleD will submit a full proposal to the ANSM (Agence Nationale du Médicament et des Produits de Santé) with RYAH providing a comprehensive solution for the French National Medical Cannabis Experimentation. As part of the proposal, RYAH will facilitate the study by providing RYAH Dose-Measuring Inhalers, Health Canada Class I certified cartridges, and HIPAA-compliant data capture software solutions. DelleD will be responsible for the HDS data hosting, authorized cartridge filling process, QC procedures, and distribution capabilities for the experiment.

Commercial Phase: Both parties intend to execute a long-term commercial strategy in France. DelleD will be commissioned to distribute RYAH dose-controlled, dry-herb inhalers, source, fill and seal the dry herb cartridges, and provide RYAH’s dedicated, secure software to the medical community in France.

“The strategic partnership with RYAH is very important for DelleD as it allows us to propose a solution to secure the use of medical cannabis flowers by French patients during the cannabis experimentation. We would be able, through our partnerships, to fill the cartridges and make the quality control in France with flowers provided by the ANSM. For years we are engaged into French medical cannabis solutions development and this is a very promising step for patients’ safe access to medical cannabis. It would facilitate the development and evaluation of our future proprietary strains for specific conditions,” said Franck Milone Delacourt, CEO of DelleD SAS.

“This strategic partnership with DelleD is an important step to further RYAH’s presence in France and Europe as a whole. This partnership combines the strength of RYAH’s clinical IoT device and software solutions with DelleD’s product development, distribution and regulatory network capability in the country of France,” said Sofiya Kleshchuk, Head of Client Relations at RYAH Medtech, Inc

Following the strategic arrangement, RYAH and DelleD will negotiate a definitive agreement (the “Definitive Agreement”) during the “Experimentation Phase”, which is estimated to begin in Q4 2020. The Definitive Agreement will include the terms and conditions, economics and performance benchmarks mandatory for the execution of the “Commercial Phase”.

“This agreement advances our ambitions to provide safe, secure and controlled plant-based dosing regimen analytics to doctors, clinics and patients specific to France. We will continue to build additional strategic relationships in Europe and worldwide to expand distribution of our precise dose-measuring devices and patented AI software analytics platform,” said Gregory Wagner, CEO of RYAH Medtech.

About RYAH Medtech, Inc.

RYAH Medtech Inc. (‘RYAH’) is a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and Licensed Processors (LPs) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption.

About DelleD SAS

DelleD SAS (‘DelleD’) is a French Biotech company specialized into plants production optimization through lighting and AI, and cannabis-based medicine development. DelleD is developing with leading edge public and private laboratories, innovative extraction methods, cannabis genetic and production optimization, galenic formulations and is already performing a pre-clinical trial in oncology. DelleD is also working on a clinical trial to be started in 2021. With his vertical integrated approach, DelleD is in contact with Ministry of Agriculture since 2017 to perform R&D on cannabis plants and to install his French excellence R&D center to develop his IP portfolio and provide innovative medical cannabis-based products.

Forward-Looking Statements

Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; ‎the benefits of RYAH’s user-generated, HIPAA-compliant data; the success of its launch in Europe; RYAH’s plan to roll-out several other clinical delivery mechanisms; the results users may receive from using RYAH products; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; legal and regulatory risks inherent in the cannabis industry; risks relating to the regulatory landscape in certain countries and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the cannabis industry; risks related to proprietary intellectual property and potential infringement by third parties; risks inherent in an agricultural business; risks associated to cannabis products manufactured for human consumption including potential product recalls; a novel business model; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and the risk associated with a business in the cannabis industry. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

For further information, please contact:

Sofiya Kleshchuk

Client Relations

+1 917 210 0543

Invest@ryahgroup.com

Click here to connect with RYAH Medtech Inc. for an Investor Presentation.

SOURCE

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The evolution of the cannabis industry in recent years continues to outperform market projections. While many attribute this unprecedented growth and positive trending to a focus on business-to-consumer models, some cannabis companies are finding significant successes leveraging white labeling partnerships to tap into a rapidly emerging marketplace that thrives on innovative business models and unique products for a growing consumer base

As the popularity of white labeling services amongst cannabis companies grows, especially in the production of fast-growing categories of value-added products like extracts, oils, edibles, and vapes, companies that are becoming an expert in co-manufacturing and have the ability to provide these services are establishing themselves as the leaders in the industry. Used as a means to expand SKU lines as well as revenue, white labeling in the cannabis industry offers companies unparalleled upside and potential for impressive profitability.

How do white labeling services work?

White labeling is a business practice that involves one company manufacturing a product, which is later sold and advertised under another company’s brand. These solutions are typically done in exchange for a flat fee or percentage of product sales depending on the terms of the agreement.

This INNspired article is brought to you by:

Ayurcann (CSE:AYUR) is a leading B2B post-harvest solution and provider focused on providing scalable custom processes and pharma-grade products to the medical cannabis industry in CanadaSend me an Investor Kit

This business-to-business solution offers a partnering company to attach their unique brand onto a “white label” product for marketing and sale to the final consumer and allows the manufacturing “white labeler” to potentially partner with different companies. Without the need to invest in infrastructure or technology. Cannabis companies can focus on building their brand and selling a wider range of products to a wide net of prospective customers.

Additionally, many also associate these white labeling solutions with toll processing, a practice in which one company provides the raw or partially processed product for another company to manufacture into a value-added product.

Access to extraction and packaging services through white label providers

White labeling services provide an ideal solution for companies who may not have the start-up capital to build a manufacturing facility, secure product licensing or have a difficult time getting a cannabis business off the ground. In these circumstances, partnering with a licensed processor that has established production and focused effort on creating a diversified range of high-quality cannabis products presents outstanding economic opportunities.

One leading example is  Ayurcann Holdings (CSE:AYUR), a B2B post-harvest solution provider focused on providing scalable custom processes and pharma-grade products to the recreational and medical cannabis industry in Canada. The company delivers a profitable business model of services and products. It operates three production divisions specializing in expert cannabis-based extraction and refinement, high-quality bulk oil sales and white label manufacturing.

White labeling options for cannabis companies

In an industry that is shifting its focus away from cultivation, more fully integrated companies delivering multiple verticals in cannabis processing and production offer an unparalleled investment opportunity that stands out from the rest. Major players in the cannabis white-labeling space offer unique exposure and retail footing that allow many companies to compete with established brands and quickly make an impact on consumers.

Ayuracann’s production offers full end-to-end outsourcing services, including proprietary product research & development, cannabis extraction & refinement and final production formulation and fulfillment. As a leading white labeling service provider, the company is focused on becoming the partner of choice for leading Canadian cannabis brands by delivering best-in-class, proprietary services, including ethanol extraction, formulation, product development and custom manufacturing.

Benefits of white labeling for cannabis companies

Data collected by Grand View Research projects the global legal cannabis market to be worth US$66.3 billion by 2025. While much of the cannabis product sold today is still the raw product, value-added consumer packaged goods are rapidly gaining significant traction throughout the cannabis industry.

White labeling services allow cannabis companies to capitalize on the latest and greatest cannabis consumer trends by expanding their portfolios to include high-demand products such as oil cartridges, extracts, topicals, CBD bath products and lotions, edibles and more. Without having to invest in the infrastructure, processing labs and manufacturing facilities required to make these products, companies can focus on releasing more products to an eager customer base. With an ever-evolving cannabis market, white label partnerships can give cannabis companies an edge over the competition.

While vertical integration can be a highly efficient strategy for large cannabis companies with the up-front capital to build the necessary infrastructure, companies without the resources to establish it take a huge risk by investing in operational and up-front costs. This includes time, building and equipment costs, license processing and finding specialized staff to grow and sustain the business.

Alternatively, outsourcing manufacturing allows a cannabis company to expand its product offerings, utilize quality formulations and establish its brand while reducing the financial risk associated with vertically integrating. Finding a compatible white labeling partnership means more time to build a brand and reach retailers and final consumers substantially faster. For cannabis companies who want to hit the ground running, white labeling offers the tools, expertise, and systems in place to make it happen.

Takeaway

Cannabis companies are using white labeling services to expand and diversify their product lines and tap into a market that is increasingly favoring value-added consumer packaged goods. For cannabis companies without fully vertically integrated operations, white-label partnerships with major players like Ayurcann Holdings offer exceptional economic efficiency and investing upside with minimized risks and infrastructural costs.

Keep reading... Show less

Dispensary reopening follows the opening of Trulieve’s 100 th Florida location

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), the largest multi-state operator (MSO) in the United States today announced the reopening of a dispensary in Lehigh Acres, Florida . The location is Trulieve’s 101 st in the state of Florida and was formerly branded as Harvest House of Cannabis.

Keep reading... Show less

Ayurcann Holdings Corp. (CSE: AYUR) (FSE: 3ZQ0) (the “Corporation” or “Ayurcann“), a Canadian cannabis extraction company specializing in the processing of cannabis and hemp to produce oils and various derivative products, announces it has retained Dolos Consultancy LTD (Dolos) and Apaton Group to manage shareholder communication, market intelligence and brand awareness for the company.

Dolos Consultancy LTD is one of the leading corporate strategy, intelligence gathering, investors analysis and capital advisories in the market. Dolos is working with a network of investors, family offices and venture capitalists, and is retained to support and accompany Ayurcann in both Investor relations and market intelligence.

Keep reading... Show less

Finalized study design and protocol mark major milestone to investigate natural Psilocybin

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to have finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived Psilocybin extract, previously announced on April 26, 2021 . This major milestone advances Numinus‘ investigation of its first proprietary psychedelic product, which was developed using a patent-pending technology submitted to the US Patent and Trade Office.

Keep reading... Show less